IL258509B2 - Methods for treating injuries or conditions related to edema in the central nervous system - Google Patents

Methods for treating injuries or conditions related to edema in the central nervous system

Info

Publication number
IL258509B2
IL258509B2 IL258509A IL25850918A IL258509B2 IL 258509 B2 IL258509 B2 IL 258509B2 IL 258509 A IL258509 A IL 258509A IL 25850918 A IL25850918 A IL 25850918A IL 258509 B2 IL258509 B2 IL 258509B2
Authority
IL
Israel
Prior art keywords
subject
sur1
hours
injury
channel inhibitor
Prior art date
Application number
IL258509A
Other languages
English (en)
Hebrew (he)
Other versions
IL258509A (en
IL258509B (en
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of IL258509A publication Critical patent/IL258509A/en
Publication of IL258509B publication Critical patent/IL258509B/en
Publication of IL258509B2 publication Critical patent/IL258509B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL258509A 2015-10-07 2016-10-07 Methods for treating injuries or conditions related to edema in the central nervous system IL258509B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (3)

Publication Number Publication Date
IL258509A IL258509A (en) 2018-05-31
IL258509B IL258509B (en) 2022-12-01
IL258509B2 true IL258509B2 (en) 2023-04-01

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258509A IL258509B2 (en) 2015-10-07 2016-10-07 Methods for treating injuries or conditions related to edema in the central nervous system

Country Status (15)

Country Link
US (4) US20180280325A1 (enExample)
EP (1) EP3359162B1 (enExample)
JP (4) JP7349786B2 (enExample)
KR (2) KR102681027B1 (enExample)
CN (2) CN108348534A (enExample)
AU (3) AU2016335767B2 (enExample)
BR (1) BR112018006925A2 (enExample)
CA (1) CA3001321A1 (enExample)
EA (1) EA201890893A1 (enExample)
ES (1) ES2940669T3 (enExample)
HK (1) HK1257542A1 (enExample)
IL (1) IL258509B2 (enExample)
MA (1) MA45574A (enExample)
MX (1) MX392466B (enExample)
WO (1) WO2017062765A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872012C (en) 2012-05-08 2017-06-20 Aeromics, Llc New methods
CN106163506A (zh) 2013-11-06 2016-11-23 埃罗米克斯公司 新配方
MA45574A (fr) * 2015-10-07 2019-05-15 Biogen Chesapeake Llc Procédés de traitement de lésions ou de pathologies liées à un dème du snc
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
EP3962466A4 (en) * 2019-05-02 2023-01-25 Biogen Chesapeake LLC METHODS OF TREATMENT OF PERSONS WITH CONtusions Of The Central Nervous System
JP7781851B2 (ja) * 2020-07-17 2025-12-08 上海森輝医薬有限公司 スルホニル尿素誘導体及びその医薬用途
US12251388B1 (en) * 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276411A1 (en) * 2002-03-20 2006-12-07 University Of Maryland, Baltimore Novel non-selective cation channel in neuronal cells and methods for treating brain swelling
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
JP4485806B2 (ja) 2002-03-20 2010-06-23 ユニヴァーシティ オブ メリーランド，ボルチモア 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
PL2868315T3 (pl) * 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
MA45574A (fr) * 2015-10-07 2019-05-15 Biogen Chesapeake Llc Procédés de traitement de lésions ou de pathologies liées à un dème du snc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276411A1 (en) * 2002-03-20 2006-12-07 University Of Maryland, Baltimore Novel non-selective cation channel in neuronal cells and methods for treating brain swelling
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KURLAND DAVID B; TOSUN CIGDEM; PAMPORI ADAM; KARIMY JASON K; CAFFES NICHOLAS M; GERZANICH VOLODYMYR; SIMARD J MARC,, GLIBENCLAMIDE FOR THE TREATMENT OF ACUTE CNS INJURY., 1 October 2013 (2013-10-01) *
SHETH ET AL,, EXPLORATORY ANALYSIS OF GLYBURIDE AS A NOVEL THERAPY FOR PREVENTING BRAIN SWELLING., 18 May 2015 (2015-05-18) *

Also Published As

Publication number Publication date
IL258509A (en) 2018-05-31
US20220125750A1 (en) 2022-04-28
EA201890893A1 (ru) 2018-09-28
EP3359162B1 (en) 2022-12-21
AU2025202620A1 (en) 2025-05-01
JP2018530564A (ja) 2018-10-18
JP7349786B2 (ja) 2023-09-25
JP2024164167A (ja) 2024-11-26
US20250017880A1 (en) 2025-01-16
KR20240105519A (ko) 2024-07-05
BR112018006925A2 (pt) 2018-10-16
MX392466B (es) 2025-03-24
KR20180063296A (ko) 2018-06-11
CA3001321A1 (en) 2017-04-13
CN108348534A (zh) 2018-07-31
AU2016335767A8 (en) 2018-06-28
MA45574A (fr) 2019-05-15
US20180280325A1 (en) 2018-10-04
JP7592768B2 (ja) 2024-12-02
JP2021073317A (ja) 2021-05-13
HK1257542A1 (zh) 2019-10-25
AU2016335767A1 (en) 2018-05-24
CN115737816A (zh) 2023-03-07
AU2022279369B2 (en) 2025-02-13
AU2022279369A1 (en) 2023-01-19
US11951085B2 (en) 2024-04-09
IL258509B (en) 2022-12-01
KR102681027B1 (ko) 2024-07-02
ES2940669T3 (es) 2023-05-10
EP3359162A4 (en) 2019-08-28
EP3359162A1 (en) 2018-08-15
WO2017062765A1 (en) 2017-04-13
US20240216309A1 (en) 2024-07-04
MX2018004286A (es) 2018-08-09
AU2016335767B2 (en) 2022-10-06
JP2023053274A (ja) 2023-04-12

Similar Documents

Publication Publication Date Title
AU2022279369B2 (en) Methods of treating injuries or conditions related to CNS edema
Le et al. Laser interstitial thermal therapy (LITT): seizure outcomes for refractory mesial temporal lobe epilepsy
Liotta Management of cerebral edema, brain compression, and intracranial pressure
US12337006B1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US20250345346A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Fogarty-Mack et al. Superselective intraarterial papaverine administration: effect on regional cerebral blood flow in patients with arteriovenous malformations
Meekins et al. The effect of body position on intraocular pressure in anesthetized horses
Ren et al. Effect of methoxymine on prevention and treatment of myocardial injury and cardiac function in elderly patients with hypotension during intraspinal anesthesia.
Kla Best Practice & Research Clinical Anaesthesiology
JP2022531312A (ja) 中枢神経系挫傷に苦しむ対象の治療方法
US20250325564A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Baig et al. NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
WO2025212154A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Hasanein et al. Extending labor epidural analgesia using lidocaine plus either dexmedetomidine or epinephrine for emergency cesarean section
JP2011500617A (ja) 血栓溶解についての新規な患者亜群